TTrialPathMatch Me to Trials
← Back to trials
RecruitingCommunity-acquired Pneumonia

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Eligible age

18+ yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).

Sponsor: University of Manitoba

You may qualify if…

  • ✓ 1. Patients ≥18 years of age
  • ✓ 2. Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
  • ✓ 1. Radiographic evidence of new or worsening infiltrate
  • ✓ 2. One or more of the following signs and/or symptoms of lower respiratory tract infection
  • ✓ i. New or increased cough or sputum production ii. Fever of \> 37.8C or temperature \< 36C iii. WBC \> 11 x 109/L or \< 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
  • ✓ 3. Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
  • ✓ 4. Hospital admission anticipated to last ≥72 hours from randomization

You may not qualify if…

  • ✕ 1. Suspected or confirmed active COVID-19 infection
  • ✕ 2. Hospital admission for \>72 hours prior to randomization
  • ✕ 3. Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
  • ✕ 4. Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
  • ✕ 5. Patients for whom the intent is to not use pharmacologic thromboprophylaxis
  • ✕ 6. Patients with an independent indication for therapeutic-dose anticoagulation
  • ✕ 7. Patients with a contraindication to therapeutic-dose anticoagulation, including:
  • ✕ 1. Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission

Where it's recruiting

Illinois

Chicago

Louisiana

Jefferson

Maine

Portland

Michigan

Dearborn

South Carolina

São José

Wisconsin

Milwaukee

Source: ClinicalTrials.gov · NCT05848713 · last updated 2026-04-21